TransCode Therapeutics, Inc.
RNAZ
$10.26
$0.848.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 73.92% | -34.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.11% | -37.73% | |||
| Operating Income | -33.11% | 37.73% | |||
| Income Before Tax | 64.61% | -104.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 64.61% | -104.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 64.61% | -104.28% | |||
| EBIT | -33.11% | 37.73% | |||
| EBITDA | -33.25% | 37.87% | |||
| EPS Basic | 92.69% | 74.17% | |||
| Normalized Basic EPS | 92.69% | 74.17% | |||
| EPS Diluted | 92.69% | 74.17% | |||
| Normalized Diluted EPS | 92.69% | 74.17% | |||
| Average Basic Shares Outstanding | 383.87% | 690.37% | |||
| Average Diluted Shares Outstanding | 383.87% | 690.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||